AbbVie Spends $10bn On ImmunoGen To Improve Chances In ADC Space

 
• By Joseph Haas

Despite writing down $4bn after the failure of Stemcentrx’s Rova-T, AbbVie will bet big again on the cancer antibody-drug conjugate space by paying a high premium for ImmunoGen, including Elahere and its R&D potential.

AbbVie Sign
AbbVie is ready to make another play in the ADC space with ImmunoGen deal • Source: Shutterstock

More from Deals

More from Business